Related Experiment Video
Updated: May 5, 2026
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation
Emma P Danhash1, Anthony C Verbeck1, Daniel Western1
1Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Introduction:
Genome-wide association studies have identified MS4A4A, a microglia-enriched gene, as a modulator of Alzheimer's disease (AD) risk. Common variants in MS4A4A affect AD susceptibility, gene expression, triggering receptor expressed on myeloid cells 2 (TREM2) signaling, and microglial transcriptional states, but the gene's functional role remains unclear.
Methods:
Using a novel model, we investigated the impact of Ms4a4a loss in the 5xFAD mouse model of amyloid beta (Aβ) accumulation.
Results:
Ms4a4a deficiency reduced steady-state Aβ levels and shortened its half-life in brain interstitial fluid. Aged 5xFAD mice lacking Ms4a4a exhibited more compact plaques and lower overall plaque burden. Microglia deficient in Ms4a4a showed a pro-inflammatory profile and elevated matrix metalloproteinase 9 (MMP-9) production, which may facilitate Aβ degradation. Notably, human carriers of the AD-resilient variant rs1582763 near MS4A4A also displayed increased cerebrospinal fluid MMP-9 levels.
Discussion:
Together, we show that Ms4a4a loss enhances Aβ clearance and reduces pathology, suggesting a protective mechanism that may inform microglia-targeted AD therapies.
Highlights:
We examined the impact of Ms4a4a loss on amyloid beta (Aβ) pathology using a mouse model of Aβ accumulation (5xFAD). Ms4a4a loss reduces overall plaque burden and increases plaque compaction. Microglia lacking Ms4a4a are more pro-inflammatory and produce more matrix metalloproteinase 9 (MMP-9). Alzheimer's disease (AD) resilience variant carriers, MS4A4A rs1582763, exhibit significantly elevated levels of cerebrospinal fluid MMP-9. Our findings suggest that reduction of MS4A4A may be a therapeutic approach for AD.
Insights
Loss of the Alzheimer's disease risk gene MS4A4A enhances amyloid-beta clearance and reduces pathology. This suggests a protective mechanism involving increased matrix metalloproteinase 9 (MMP-9) for potential Alzheimer's disease therapies.
Area of Science:
- Neuroscience
- Genetics
- Immunology
Background:
- Genome-wide association studies link MS4A4A, a microglia-enriched gene, to Alzheimer's disease (AD) risk.
- Common variants in MS4A4A influence AD susceptibility, TREM2 signaling, and microglial states, but its precise function is unknown.
Purpose of the Study:
- To investigate the functional role of Ms4a4a in Alzheimer's disease pathology using a mouse model.
- To determine the impact of Ms4a4a deficiency on amyloid-beta (Aβ) accumulation and clearance.
Main Methods:
- Utilized a novel model to study Ms4a4a loss in the 5xFAD mouse model of Aβ accumulation.
- Analyzed Aβ levels, plaque characteristics, microglial profiles, and MMP-9 production.
Main Results:
- Ms4a4a deficiency reduced steady-state Aβ levels and accelerated its clearance.
- Mice lacking Ms4a4a exhibited more compact plaques and a lower overall plaque burden.
- Ms4a4a-deficient microglia displayed a pro-inflammatory profile and elevated MMP-9 production, correlating with AD-resilient human variants.
Conclusions:
- Ms4a4a loss enhances Aβ clearance and reduces Alzheimer's disease pathology.
- Elevated MMP-9 levels in Ms4a4a-deficient microglia and human AD-resilient variant carriers suggest a protective mechanism.
- Targeting MS4A4A may represent a novel therapeutic strategy for Alzheimer's disease.
